Evidence & concentration worksheet · Healing & Recovery
BPC-157 10 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in gastric juice. Research attention centres on its apparent effect on angiogenesis — the formation of new blood vessels — and on the up-regulation of growth-factor receptors that tissue relies on to repair itself.
In preclinical models it has been associated with faster healing of tendon, ligament and muscle, protection of the gut lining, and modulation of the nitric-oxide pathway that governs local blood flow. None of this is established in controlled human trials, and BPC-157 is not an approved drug in most jurisdictions — the protocol here is an educational reference, not a clinical recommendation.
Benefits & side effects
- Studied for connective-tissue repair (tendon, ligament, muscle) in animal models.
- Associated with cytoprotection of the gastrointestinal tract in preclinical work.
- Generally reported as well tolerated at the doses studied; occasional mild injection-site reactions.
- Human efficacy and long-term safety are not established — treat all claims with caution.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- NIH / NCATS — BPC-157 investigational compound record (2026)
- Current Pharmaceutical Design — Stable gastric pentadecapeptide BPC 157: gastrointestinal research review (2011)
- Pharmaceuticals — BPC-157 literature and patent review (2025)
- Journal of Applied Physiology — BPC-157 and tendon-cell outgrowth, survival, and migration (2011)
- Journal of Orthopaedic Research — BPC-157 in a transected rat Achilles-tendon model (2003)
- Regulatory Toxicology and Pharmacology — Preclinical safety evaluation of BPC-157 (2020)
- ClinicalTrials.gov — NCT02637284 safety and pharmacokinetics study record (2015)
- Alternative Therapies in Health and Medicine — Retrospective intra-articular BPC-157 report (2021)
- Alternative Therapies in Health and Medicine — Small interstitial-cystitis pilot report (2024)
- U.S. FDA — Bulk substances that may present significant compounding safety risks (2026)
- U.S. FDA — July 2026 Pharmacy Compounding Advisory Committee meeting (2026)
- USADA — BPC-157 is prohibited as an experimental peptide (2026)
- WADA — 2026 Prohibited List (2026)
- HSS Journal — Systematic review of emerging BPC-157 use in orthopaedic sports medicine (2025)
Other vial sizes